LONDON, Ontario and BOSTON, March 10, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics , (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing it’s Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes (T1D), today announced the appointment of Pericles (Perry) Calias, Ph.D., as Chief Development Officer (CDO) and Head of R&D. Dr. Calias brings over two... Read More

LONDON, Ontario and BOSTON, March 05, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics , (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch Bio-hybrid Organ as a functional cure for type 1 diabetes, today announced a CAD$1,000,000 unsecured convertible debenture financing with Dr. Steven Sangha, a current Sernova shareholder and board member. Proceeds from... Read More

LONDON, Ontario and BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics , (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing it’s Cell Pouch bio-hybrid organ as a functional cure for type 1 diabetes, today announced that the U.S. Food and Drug Administration (FDA) has cleared it’s Investigational New Drug (IND) application to evaluate the Company’s Cell... Read More

LONDON, Ontario and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics , (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for type 1 diabetes, today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to evaluate the Company’s Cell... Read More

LONDON, Ontario and BOSTON, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics , (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for Type 1 diabetes (T1D), today announced the appointment of Ross Haghighat as Chair of the Board. With a proven track record in driving successful innovations, strategic growth... Read More

LONDON, Ontario and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for type 1 diabetes, today announced results from its annual and special general meeting of shareholders (the “Meeting”) held virtually via live audio webcast on January 10, 2025. At the... Read More

LONDON, Ontario and BOSTON, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for type 1 diabetes, today announced that it will hold its annual general and special meeting of shareholders (the “Meeting”) on Friday, January 10, 2025, at 1:00pm ET. Due to the recent postal... Read More

Signed Letter of Intent with ‘Project REEM Ventures’ for Product Development and Commercialization in the Kingdom of Saudi Arabia Renowned Diabetes Expert Dr. Robert Gabbay to Serve as Clinical Advisor Town Hall Call to be Held on December 13; AGM Circular Available on December 6 LONDON, Ontario and BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative... Read More

Experienced leadership team positions company to advance Cell Pouch™ bio-hybrid organ programs. LONDON, Ontario; BOSTON, Massachusetts – TheNewswire – October 11, 2024 – Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company currently executing a phase 1/2 clinical study with its’ Cell Pouch™ bio-hybrid organ in type 1 diabetes is pleased to announce key new appointments to its... Read More

LONDON, Ontario; BOSTON, Massachusetts – October 3, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, announced that its CEO, Jonathan Rigby, will be presenting at the 2024 Cell & Gene Meeting on the Mesa being held October 7-9, 2024, at the Arizona Biltmore... Read More

LONDON, Ontario; BOSTON, Massachusetts – September 19, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, announces today that David Paterson Ph.D. will join Sernova’s Board of Directors effective immediately. “I am pleased to have been able to attract David’s... Read More

Abundant, richly vascularized and functioning islets observed throughout all chambers of Sernova’s Cell Pouch more than 5 years after islet transplantation Histological data confirmation of healthy beta, alpha and delta cells secreting insulin, glucagon, and somatostatin in all Cell Pouch Chambers Sernova’s Cell Pouch safely contains its therapeutic cells and provides full retrievability using conventional instruments and... Read More

LONDON, Ontario – September 5, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical- stage company and leader in cell therapeutics, today announced it will be participating in the upcoming H.C. Wainwright 26 th Annual Global Investment Conference being held September 9 to 11, 2024 in New York City at the Lotte New York Palace. Company management will also be participating in one-on-one... Read More

LONDON, ONTARIO – TheNewswire - September 4, 2024 - Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that it has closed its non-brokered, private placement in the amount over $5.2 million , which includes over-subscriptions of more than $1.2 million. All securities issued pursuant to the private placement are subject to a hold period of four months under applicable provincial securities laws in... Read More

LONDON, ONTARIO – TheNewswire - August 29, 2024 - Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that its non-brokered, private placement offering of $4M is oversubscribed with $4.7M of binding agreements received. The closing will occur on Tuesday September 3, 2024, subject to TSX approval. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the... Read More

LONDON, ONTARIO – TheNewswire - August 20, 2024 - Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH) is pleased to announce that the Company has secured over $2 million in lead orders in connection with a non-brokered private placement offering (the “Offering”) for up to $4 million units priced at a premium to the market. Each unit is priced at $0.25, and consists of one common share and one warrant. Each warrant is priced... Read More

Dr. Piotr Witkowski MD PhD, Professor of Surgery and Director of the Pancreatic and Islet Transplant Program, and his islet transplant team at University of Chicago Medicine authored an abstract that will be presented, including new data from the ongoing Phase I/II clinical trial of the Cell Pouch System™ in patients with type 1 diabetes (T1D). LONDON, Ontario; BOSTON, Massachusetts – August 15, 2024 – TheNewswire – Sernova... Read More

LONDON, Ontario and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- August 12, 2024. Sernova Corp. (“ Sernova ” or the “ Company ”) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, led by an ongoing phase 1/2a clinical trial in type 1 diabetes, is pleased to announce Mr. Jonathan Rigby as the... Read More

LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - July 15, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases such as Type 1 Diabetes, today announced that the Board of Directors has appointed Jonathan Rigby, who previously joined as a Director in May, as Executive... Read More

To date Sernova reports 7 patients in its Phase I/II type 1 diabetes clinical trial achieved freedom from insulin injections and demonstrate blood sugar control in the non-diabetic range (HbA1c 6.5%); 6 patients have reached between 5.5 and 50 months of sustained insulin independence and freedom from severe hypoglycemic episodes; Completion of enrollment in Cohort 2 LONDON, Ontario; BOSTON, Massachusetts – June 25, 2024 –... Read More

LONDON, Ontario; BOSTON, Massachusetts – June 12, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, today announced that it is not proceeding with its public offering of units and is withdrawing its preliminary short form prospectus filed on June 6, 2024. The... Read More

LONDON, ON and BOSTON , June 6, 2024 /CNW/ - Sernova Corp. (" Sernova " or the " Company ") (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH) is pleased to announce that it has filed a preliminary short form prospectus in connection with a best efforts marketed public offering (the " Offering ") of units of the Company (the " Units "). The Offering is being led by Stifel Nicolaus Canada Inc., as lead agent (the " Lead Agent ") and... Read More

LONDON, Ontario; BOSTON, Massachusetts – May 28, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, announces today that Jonathan Rigby will join Sernova’s Board of Directors effective immediately. “We are excited to welcome Jonathan to Sernova’s Board of... Read More

LONDON, Ontario; BOSTON, Massachusetts – TheNewswire – May 1, 2024, Sernova Corp. (“Sernova” or the “Corporation”) (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH) a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, is pleased to announce results from its Annual General Meeting of Shareholders (the “AGM”) held virtually via live audio webcast, on... Read More

Dr. Philip Toleikis to retire as of April 30, 2024 Cost savings from restructuring and strategic transformation anticipated to extend runway Board rebuild underway LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - April 25, 2024 – Sernova Corp. (TSX:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic... Read More

Dr. Daniel Mahony to step down to pursue new commitment LONDON, Ontario; BOSTON, Massachusetts – April 22, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment of chronic diseases, announces today that Dr. Bernd Muehlenweg, Senior Vice President of Global Business Development at... Read More

Type 1 diabetes (T1D) Cohort 2 patient data demonstrates favorable islet engraftment and long-term survival of human donor islets in the Cell Pouch First treated Cohort 1 patient in the T1D clinical trial to celebrate four years of insulin independence and normalized HbA1c With recent positive findings in post-surgical hypothyroidism large animal study, Sernova anticipates filing an Investigational New Drug (IND) application... Read More

LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - March 11, 2024 – Sernova Corp. (TSX:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage company focused on providing regenerative medicine therapeutics to patients with chronic conditions, today announced that Nicholas J. Rossettos, CPA has joined Sernova on a consulting basis as interim Chief Financial Officer (CFO). With a wealth of experience in financial leadership... Read More

Recently completed recruitment of all 7 patients in Cohort 2 Anticipates additional data from Cohort 2 of Phase 1/2 clinical trial evaluating its enhanced 10-channel Cell Pouch in patients with type 1 diabetes (T1D) in Q1/24 Expects to report preclinical data supporting an IND application to evaluate the use of therapeutic cells in combination with Cell Pouch in patients with post-operative hypothyroidism LONDON, Ontario;... Read More

LONDON, Ontario and WINDHAM COUNTY, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for the company’s Hemophilia A program. The FDA grants orphan designation, also... Read More

LONDON, Ontario and WINDHAM COUNTY, Conn., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced an update on its conformal coating immune protection technology program, that is used in combination with the Cell Pouch™. The goal of the program is to eliminate the need for chronic immunosuppression medications,... Read More

All six patients in the first cohort (Cohort A) were successfully implanted with the 8-channel Cell Pouch System with post-transplant follow-up periods ranging from 6 months to 3.5 years; 5 of 6 patients in Cohort A discontinued insulin therapy (insulin independent) following islet transplantation into the Cell Pouch and modest islet top-up via portal vein. All 6 patients achieved HbA1c values in the non-diabetic range... Read More

Dr. Piotr Witkowski presenting new data from ongoing Phase 1/2 clinical trial of the Cell Pouch System™ in patients with type 1 diabetes (T1D) Dr. Alice Tomei presenting preclinical data on transplantation of conformal coated islet cells in pre-vascularized Cell Pouch LONDON, Ontario and WINDHAM COUNTY, Conn., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company... Read More

LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced new preclinical data for its novel cell therapy platform, the Cell Pouch System, as a potential treatment for post-operative hypothyroidism at the 2023 American Thyroid Association (ATA) Annual Meeting being held in... Read More

LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has rescheduled the investor and analyst conference call previously scheduled for September 15 at 10 a.m. Eastern Time. The call will now occur on September 22 at 10 a.m. Eastern Time. The business strategy and update... Read More

Introduction of New CEO Cynthia Pussinen and Recently Appointed Chief Business Officer, Dr. Modestus Obochi, on September 15, 2023 Business Update, Strategy & Outlook Call on October 5, 2023 LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will host two investor and... Read More

LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Sernova Corp . (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today provided a development update on its exclusively licensed, proprietary conformal coating immune protection technology, being advanced in combination with the Cell Pouch™ through a collaboration with Dr. Alice Tomei at the... Read More

Industry veteran with deep commercial experience joins to lead the next stage of growth and development Dr. Philip Toleikis will serve as Chief Technology Officer Sernova to host investor calls LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced that its Board of Directors... Read More

LONDON, Ontario, July 26, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, today announced the appointment of Modestus Obochi, Ph.D., MBA, a veteran dealmaker and strategic leader with 25+ years of biotech and pharmaceutical industry experience, as Chief Business Officer effective September 8, 2023. “Dr. Obochi brings additional... Read More

In the first cohort of the ongoing Phase 1/2 clinical trial, the first 5 patients to complete protocol-defined islet transplants achieved insulin-independence for ongoing periods of 6 to 38 months. Following islet transplants to the 8-channel Cell Pouches, patients in the first cohort required only modest islet top-up via portal vein to achieve insulin independence, supporting the contribution to blood glucose control from... Read More

LONDON, Ontario, June 22, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, will be presenting updated interim data from its ongoing Phase 1/2 clinical trial of the Cell Pouch System™ in patients with type 1 diabetes (T1D) and hypoglycemia unawareness at the American Diabetes Association (ADA) 83rd Scientific Sessions, to be held June... Read More

LONDON, Ontario, June 16, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be participating in the upcoming symposia-cel Truist Securities Cell Therapy Symposium being held June 27, 2023 in New York City. Company management will also be participating in one-on-one investor meetings at the conference. symposia-cel... Read More

LONDON, Ontario, May 31, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a clinical-stage company and leader in cell therapeutics, today announced the outcomes from a strategic and executive leadership review conducted by its Board of Directors (the “Board”). Following the recent 2023 Annual General Meeting of Shareholders (the “AGM”), the Sernova Board welcomed Mr. Brett Whalen, Dr. Steven... Read More

LONDON, Ontario, May 03, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it has entered into a preclinical research collaboration with AstraZeneca (LSE/STO/Nasdaq:AZN) to evaluate the use of Sernova’s Cell Pouch System™ in combination with AstraZeneca’s novel therapeutic cells. “Sernova has developed a novel cell therapy... Read More

Sernova Corp. (“ Sernova ” or the “ Corporation ”) (TSX:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine company and leader in cell therapeutics focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D) and other chronic diseases, is pleased to announce results from its Annual General Meeting of Shareholders (the “ AGM ”), held virtually via live audio webcast on April 27, 2023.... Read More

TORONTO , April 25, 2023 /CNW/ - The group of longstanding shareholders (the "Concerned Shareholders") of Sernova Corp (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH) (XETRA: PSH) ("Sernova" or the "Company") wishes to thank all shareholders for their participation in electing the next Board of Directors. The intended function of the Board is to represent all shareholders and other stakeholders in setting the course, the tone, and the... Read More

Evotec’s scalable GMP manufacturing process has been designed to produce induced pluripotent stem cell (iPSC)-derived islet-like clusters (ILCs) with high insulin-producing beta cell content as well as glucagon and somatostatin (produced by alpha cells and delta cells, respectively), similar to human islets The ILCs are cryopreserved during manufacturing, enabling storage of mass volumes and cost efficient on-demand... Read More

Following Institutional Shareholder Services’ positive recommendations, Glass Lewis is the second independent, third-party proxy advisory firm to recommend Sernova’s shareholders vote FOR all management’s director nominees using ONLY management’s WHITE proxy. Glass Lewis does not believe Sernova’s dissident shareholders have compiled a sufficiently compelling case to warrant investor support and refers to their arguments as... Read More

TORONTO , April 17, 2023 /CNW/ - The group of longstanding shareholders (the "Concerned Shareholders") of Sernova Corp (TSX: SVA) (OTCQB: SEOVF) (FSE: PSH) (XETRA: PSH) ("Sernova" or the "Company") maintains that the decrease in share valuation, lack of investor updates and progress relating to clinical studies, deficiencies relating to business development and partnerships, unjustified compensation as well as corporate... Read More

ISS, an independent, third-party proxy advisory firm, recommends Sernova’s shareholders vote FOR all management’s director nominees using ONLY management’s WHITE proxy. ISS notes the dissidents failed to present a detailed explanation of their case and there does not seem to be a compelling case that change at Sernova is warranted at this time. Shareholders who have questions or need assistance with voting their shares... Read More

ISS, an independent, third-party proxy advisory firm, recommends Sernova’s shareholders vote FOR all management’s director nominees using ONLY management’s WHITE proxy. ISS notes the dissidents failed to present a detailed explanation of their case and there does not seem to be a compelling case that change at Sernova is warranted at this time. Shareholders who have questions or need assistance with voting their shares... Read More

LONDON, Ontario, April 10, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced that President and Chief Executive Officer, Dr. Philip Toleikis, will present at the upcoming annual Cell & Gene Meeting on the Med to be held April 12-14, 2023 at the Hotel Arts Barcelona in Barcelona, Spain and livestreamed globally. Panel:... Read More

The dissident director nominees declined to follow proper protocol to participate in Sernova’s board renewal process and instead are imposing themselves on the Company through a costly and disruptive proxy battle Management and the Board have placed Sernova in a position to bring value to shareholders and in a challenging time for companies in the biotech sector, Sernova’s share price is up 17% year-to-date compared to an 8%... Read More

Concerned shareholder group has issued an information circular and letter to shareholders outlining reasons for change TORONTO , April 3, 2023 /CNW/ - A group of longstanding shareholders of Sernova Corp (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH) ("Sernova" or the "Company") who currently own approximately 12% of the Company's shares have concerns regarding the performance of Sernova's Board (the "Concerned Shareholders").... Read More

TORONTO , March 22, 2023 /CNW/ - Betty Anne Millar has filed a notice (the "Notice") with Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) ("Sernova" or the "Company") for the nomination of two highly experienced independent directors to be elected to the board of Sernova at the annual general meeting to be held on April 27, 2023 (the "Meeting"). Mrs. Millar, together with joint actors (the "Group of Shareholders"), holds directly... Read More

LONDON, Ontario, March 22, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, is pleased to announce that an abstract has been selected for an oral podium presentation at the upcoming American Diabetes Association (ADA) 83 rd Scientific Sessions, to be held from June 23-26, 2023, in San Diego, CA. It will also be published on the journal... Read More

LONDON, Ontario, March 14, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that an abstract has been selected for an oral presentation at the 4 th International Pancreas and Islet Transplant Association (IPITA) / Harvard Stem Cell Institute (HSCI) / Juvenile Diabetes Research Fund (JDRF) Summit, to be held from April... Read More

Third patient now implanted with higher capacity, 10-chamber Cell Pouch Company anticipates first interim data from second cohort in Q4 2023 LONDON, Ontario, March 08, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that the first two patients in the second cohort of its active U.S. Phase 1/2 clinical trial for the... Read More

LONDON, Ontario, March 02, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be participating in the upcoming 35th Annual Roth Conference being held March 12-14, 2023 and the Oppenheimer 33rd Annual Healthcare Conference, taking place March 13-15, 2023. Company management will also be participating in one-on-one... Read More

Preclinical proof of concept study demonstrates that thyroid auto-transplantation into the Cell Pouch can restore thyroid hormone production following removal of the thyroid gland Sernova has engaged with regulatory authorities towards initiating clinical development of a prospective therapy for hypothyroidism LONDON, Ontario, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a... Read More

First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization to treat patients with Type 1 Diabetes (T1D) and severe hypoglycemia iPSC islet-like cluster manufacturing scale-up and tech transfer activities are well under way in preparation for first human clinical evaluation T1D preclinical models with iPSC derived... Read More